Your session is about to expire
← Back to Search
Metformin for Chronic Lymphocytic Leukemia
Study Summary
This trial will study whether metformin is an effective treatment for people with CLL.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 156 Patients • NCT02002221Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently taking medication for diabetes.My lymph nodes have been swollen for more than 3 months.My condition worsened after treatment with specific cancer drugs.I am between 18 and 79 years old.I have an untreated del11q mutation.My kidney function is normal or only mildly reduced.I have diabetes with high blood sugar or HgbA1C levels.I need urgent chemotherapy for my active CLL.You are expected to live for more than 12 months.My cancer cells test positive for CD19 or CD20, and also for CD23 and CD5.You have had allergic reactions to metformin or similar medications in the past.You have a problem with drinking too much alcohol, like being addicted to it or regularly having more than 3 drinks a day.I received my last treatment for CLL less than 30 days ago.I am not pregnant nor planning to become pregnant, confirmed by a test.I do not have any severe illnesses or social situations that would prevent me from following the study's requirements.I have had metabolic acidosis in the past.I do not have an active infection that could lead to sepsis.I have been diagnosed with chronic lymphocytic leukemia.I am able to care for myself and move around.My organs are functioning normally.My kidney function, measured by serum creatinine, is within the normal range.I have severe heart failure.
- Group 1: Metformin (Glucophage)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Metformin been granted regulatory sanction by the FDA?
"Due to the Phase 2 status of Metformin, our team at Power has assigned it a safety rating of 2 out of 3 due to limited efficacy data."
To what extent are potential participants eligible for this research endeavor?
"Eligibility for this medical trial calls for patients with leukemia that are between 18 and 80 years old. 40 people in total need to be enrolled."
Does this research protocol include participants aged 40 and beyond?
"This medical trial seeks participants who are between 18 years old and their octogenarian birthday."
Is there evidence of Metformin being utilized in prior research projects?
"Presently, 170 Metformin clinical trials are ongoing. Of those, 43 have reached Phase 3 and the majority of them occur in Rockville, Maryland. Across 1903 sites across the US though, researchers can conduct studies on Metformin's efficacy."
What is the total enrollment tally for this medical trial?
"Affirmative. Clinicaltrials.gov contains evidence that this clinical trial is actively recruiting 40 patients from 1 site, having been initially posted on November 1st 2012 and recently edited on May 11th 2022."
What ailments typically respond positively to Metformin treatment?
"Exercise-related conditions can frequently be managed with Metformin; however, it is also beneficial for treating other medical complications including type 1 diabetes mellitus, diabetic ketoacidosis, and polycystic ovary syndrome."
Is this experiment still open to participants?
"Current information on clinicaltrials.gov confirms that this medical study is actively recruiting subjects for participation. This trial was first listed online on November 1st, 2012 and its details were last updated on May 11th, 2022."
Share this study with friends
Copy Link
Messenger